Robinet 2001

Methods	RCT: enrolled: 176 evaluated: 171
Participants	Inclusion: 1. metastatic non‐small cell lung cancer 2. at least one measurable brain metastasis 3. ECOG performance two or less 4. good renal and hematologic function Exclusion: 1. recent myocardial infarction, congestive heart failure or arrhythmia 3. prior chemotherapy or brain radiotherapy 4. previous cancer (non‐melanoma skin cancer or in situ cervix cancer allowed)
Interventions	early versus delayed WBRT and concurrent cisplatin and vinorelbine chemotherapy
Outcomes	1. Survival 2. Progression‐free survival 3. Response
Notes	QS = 3